Health and Healthcare
What's Next for the Proteostasis Cystic Fibrosis Pipeline
Published:
Last Updated:
Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares were absolutely crushed on Tuesday after the firm announced midstage data from its cystic fibrosis (CF) study. Ultimately, the results from the study were mixed, and considering this stock was valued less than $1 only two months ago, investors quickly sent shares lower.
The company announced positive topline results from its Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations in F508del homozygous and heterozygous CF subjects.
The compounds were generally well tolerated, and the majority of reported adverse events were mild to moderate in severity. Most subjects enrolled in the Phase 2 study carried a high disease burden, with over 80% of subjects trying and failing to enroll into trials of currently approved modulators due to ineligibility.
Based on the results, Proteostasis is planning to launch a global, Phase 3 More trial in CF subjects with the common F508del homozygous mutation, beginning in 2020. The More trial complements the Choices trial. Choices, which is also expected to initiate in 2020, will be the first-ever personalized medicine-based study in CF.
Geoffrey Gilmartin, M.D., MMSc, chief medical officer of Proteostasis, commented:
We look forward to advancing our triple combination into a pivotal study next year, while simultaneously pursuing a personalized medicine clinical and regulatory pathway together with the HIT-CF funded through the European Commission Horizon 2020 program. We are very grateful to the patients, their families and healthcare providers who have supported PTI in our pursuit of delivering more choices to people with CF and to providing the benefit of CFTR modulators to all, regardless of mutation status.
Shares of Proteostasis were last seen down 57% at $1.84, in a 52-week range of $0.61 to $4.72. The consensus price target is $7.00.
Travel Cards Are Getting Too Good To Ignore (sponsored)
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.